Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.30
Handel nachbörslich:
.26
0.26
+
Schlusskurs vom Vortag:
$0.30
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$1.13M
Einnahmen:
$132.70K
Nettoeinkommen (Verlust:
$-25.04M
KGV:
0.00
EPS:
-20.6616
Netto-Cashflow:
-
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$3.60
Altamira Therapeutics Ltd Stock (CYTO) Company Profile
Firmenname
Altamira Therapeutics Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie CYTO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CYTO
Altamira Therapeutics Ltd
|
0.00 | 1.13M | 132.70K | -25.04M | 0 | -413.23 |
|
VRTX
Vertex Pharmaceuticals Inc
|
410.65 | 105.75B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.68 | 78.76B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
632.04 | 37.79B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.50 | 31.28B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.77 | 27.28B | 3.30B | -501.07M | 1.03B | -2.1146 |
Altamira Therapeutics Ltd Aktie (CYTO) Neueste Nachrichten
Nasdaq de-lists Altamira shares - Royal Gazette
Altamira Therapeutics Announces Transition from NASDAQ to OTC Markets - GlobeNewswire
Altamira Therapeutics Moves to OTCQB After Nasdaq Delisting Over Minimum Bid Requirements - StockTitan
Altamira Therapeutics (NASDAQ:CYTO) Stock Price Down 1.3% – Here’s What Happened - Defense World
CYTO stock plunges to 52-week low, touches $0.4 By Investing.com - Investing.com South Africa
ARMISTICE CAPITAL, LLC Acquires New Stake in Altamira Therapeuti - GuruFocus.com
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
CYTO stock plunges to 52-week low, hitting $0.57 amid market challenges - Investing.com Australia
Here's Why Auris (CYTO) Is a Great 'Buy the Bottom' Stock Now - Nasdaq
Altamira Therapeutics and Nuance Pharma Enter Into Exclusive Licensing and Distribution Agreement for Bentrio in China and Additional Asian Markets - AsiaOne
Altamira Therapeutics faces Nasdaq delisting over share price - Investing.com India
Altamira Therapeutics Provides Update on Nasdaq Listing - The Manila Times
Altamira Therapeutics Faces Nasdaq Delisting - TipRanks
Altamira Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com UK
CYTO stock plunges to 52-week low, touches $0.65 By Investing.com - Investing.com South Africa
CYTO stock plunges to 52-week low, touches $0.65 - Investing.com India
Altamira Medica obtains extended ISO 13485 certification By Investing.com - Investing.com South Africa
Altamira Medica obtains extended ISO 13485 certification - Investing.com
Altamira Therapeutics Announces Extended ISO 13485 Quality - GlobeNewswire
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray - StockTitan
Earnings call: Altamira Therapeutics focuses on RNA delivery growth By Investing.com - Investing.com Australia
Earnings call: Altamira Therapeutics focuses on RNA delivery growth - Investing.com
Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2024 Earnings Call Transcript - Insider Monkey
Altamira Therapeutics Ltd (CYTO) Q2 2024 Earnings Call Transcript Highlights: Key Financial and ... By GuruFocus - Investing.com Canada
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results - GlobeNewswire
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics - Digital More
Nuance Pharma Announces Expansion of Bentrio License and Distribution Agreement with Altamira Therapeutics in East and South East Asia - The Manila Times
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 - GlobeNewswire
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering - GlobeNewswire
Altamira Issues Pre-Funded Share Purchase Warrant - TipRanks
Altamira Therapeutics announces $4 million public offering - Investing.com India
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering - The Bakersfield Californian
Altamira Therapeutics Announces Expansion of Bentrio - GlobeNewswire
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with - The Bakersfield Californian
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia - StockTitan
Trending tickers: latest investor updates on Microsoft, Bitcoin, Altamira and Ashtead - Yahoo Finance UK
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 - GlobeNewswire
REPEAT — Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO) - ForexTV.com
Finanzdaten der Altamira Therapeutics Ltd-Aktie (CYTO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.50%
1.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):